WillItSurvive
Pharma and healthcare groups · United States

BioMarin Pharmaceutical

biomarin.com ↗

BioMarin makes enzyme and gene therapies for rare genetic diseases worldwide.

Defensible for now
Assessed 24 July 2026 · Evidence as of 24 July 2026
Real protection, with named pressure against it.
On the recordSince 24 July 2026 · Checkable from Q2 2026 · Every call on the record Checkpoint: Ascendis launches Yuviwel commercially in the U.S., competing head to head with VOXZOGO
The call

BioMarin's rare disease business keeps growing, but its biggest product now faces a funded rival and new debt from the Amicus deal.

BioMarin makes medicines for rare genetic diseases and generates about $3.2 billion in yearly revenue. The company's main strength is that its drugs are protected by patents and special government exclusivity rights across 70 countries, making them hard to copy or replace quickly. However, nearly one-third of BioMarin's revenue comes from one drug called VOXZOGO, which treats a rare bone disorder, and a competitor called Ascendis has just won FDA approval for a similar drug (Yuviwel) launching in mid-2026. BioMarin also just borrowed $3.7 billion to buy another company called Amicus, so it now carries large debt on top of this competitive threat. The key question is whether VOXZOGO will lose significant sales to Yuviwel after the competitor launches, and whether the Amicus deal helps or hurts the company's financial health enough to matter.

Why
01
AI pressure: None apparent. No AI product currently threatens BioMarin's rare disease drug sales or its rare-patient distribution network. Could AI do the core job? Unlikely.
02
Bigger players: Ascendis Pharma (Yuviwel). Ascendis's FDA-approved weekly CNP drug Yuviwel directly targets VOXZOGO, BioMarin's $927M achondroplasia product, with a 2026 launch. Could a giant copy it? No, they are blocked.
03
What protects it. Orphan exclusivity, patents, and a 55-country rare-disease distribution network make switching costly for doctors and payers.
What would change this call
Ascendis Yuviwel U.S. commercial launch and early prescription uptake data in 2026. Shows whether achondroplasia patients/doctors are switching away from VOXZOGO.
Federal Circuit ruling (March 26, 2026) and ITC trial outcome on VOXZOGO-related patents. Determines whether litigation can slow or block Yuviwel's market entry.
BioMarin's Q2 2026 earnings call VOXZOGO revenue and Amicus integration update. Reveals actual share erosion pace and whether the added Amicus debt is being absorbed smoothly.
Key numbers
  • FY2025 revenue $3.22 billion, up 13% (2025-12-31)
  • VOXZOGO revenue $927 million, up 26% (2025-12-31)
  • FY2026 guidance $3.825 to $3.925 billion (2026-05-04)
Named risks
  • Ascendis Yuviwel eroding VOXZOGO, ~29% of FY2025 revenue, starting 2027. Severity: high
  • ~$3.7 billion new debt from Amicus acquisition raises leverage. Severity: medium
  • Ongoing ITC/Federal Circuit patent litigation outcome uncertain vs Ascendis. Severity: medium
  • ROCTAVIAN market withdrawal signals gene-therapy commercial failure. Severity: medium
  • KUVAN legacy PKU drug declining 18% YoY due to generics. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Ascendis PharmacontestingYuviwel FDA-approved March 2026 as direct VOXZOGO rival; ITC/Federal Circuit litigation ongoing through April 2026
BridgeBio Pharmagaining onDeveloping oral achondroplasia candidate reported to have positive data, per March 2026 trade press
Sanofi/GenzymecontestingALDURAZYME marketing partner and major lysosomal storage disease competitor
Questions people ask
Is BioMarin Pharmaceutical profitable in 2026?
Yes, cash-generating: FY2025 operating cash flow hit $828 million (+45% YoY) with non-GAAP diluted EPS of $3.15, and Q1 2026 revenue of $766 million beat consensus, per BioMarin's Feb 23 2026 and May 4 2026 results.
Who owns BioMarin?
BioMarin is publicly traded on NASDAQ under BMRN with no controlling parent. Activist Elliott Investment Management took a stake exceeding $1 billion in Nov 2023 and settled in Dec 2023, adding three independent directors and a review committee.
Is VOXZOGO at risk from Ascendis Pharma's Yuviwel?
Yes. Ascendis's once-weekly Yuviwel won FDA approval in March 2026 as a direct rival to VOXZOGO, BioMarin's $927 million (FY2025, +26% YoY) flagship drug, and BioMarin's own 2026 guidance already assumes stronger competitive erosion starting in 2027.
Could AI replace BioMarin's rare-disease drug development?
Unlikely soon. AI tools like AlphaFold and BioMarin's Deep Genomics collaboration speed discovery and cut admin work (its CDIO cited up to 40% time savings, June 2026), but cannot replace patents, orphan-drug exclusivity, clinical trial execution, or its 70+ country patient-finding infrastructure.
Is BioMarin doing layoffs in 2026?
No layoffs are reported; headcount rose to 3,221 employees in 2025 from 3,040 in 2024 (+5.95%) per 10-K data, and the company just closed the $4.8 billion Amicus Therapeutics acquisition on April 27, 2026, which will likely add staff.
What happened to BioMarin's ROCTAVIAN gene therapy?
BioMarin withdrew ROCTAVIAN, its hemophilia A gene therapy, from the market in February 2026 after it generated only $36 million in 2025 and no buyer was found, taking a roughly $240 million GAAP charge.
Timeline
  • 2026-05-04Q1 2026 revenue $766M beats consensus; FY2026 guidance raised to $3.825-3.925B
  • 2026-04-27Closed $4.8B Amicus Therapeutics acquisition, funded with ~$3.7B new debt
  • 2026-03-26Federal Circuit ruling issued in Ascendis Pharma patent dispute
  • 2026-03-02Ascendis Pharma's Yuviwel, a direct VOXZOGO rival, wins FDA approval
  • 2026-02-24BioMarin withdraws ROCTAVIAN from market, takes ~$240M charge
  • 2026-02-23FY2025 results: revenue $3.22B (+13% YoY), VOXZOGO $927M (+26%)
  • 2025-12-15Announces definitive agreement to acquire Amicus Therapeutics for ~$4.8B
  • 2025-07-01Acquires Inozyme Pharma, adding BMN-401 for ENPP1 deficiency
  • 2023-12-20Settles with activist Elliott Investment Management, adds 3 directors
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources